Tilray Medical Europe

Tilray Medical Europe

Pharmaceutical Manufacturing

Pioneering the Future of Medicinal Cannabis

About us

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the biggest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents. For more information on Tilray Medical, visit www.tilraymedical.eu.com Tilray Medical is the medical division of Tilray Brands, Inc (Nasdaq: TLRY; TSX:TLRY), a leading global cannabis-lifestyle and consumer package goods company. For more information on Tilray Brands, Inc visit www.tilray.com

Industry
Pharmaceutical Manufacturing
Company size
201-500 employees
Type
Public Company
Founded
2013
Specialties
medicinal cannabis and medical cannabis

Employees at Tilray Medical Europe

Updates

  • Tilray Medical Europe reposted this

    View organization page for Tilray Brands, Inc., graphic

    77,237 followers

    We are thrilled to announce the launch of our first commercial “Grown in Germany” medical cannabis products! This milestone marks a significant achievement for Tilray Medical and our Aphria RX GmbH facility, as we introduce the first medical cannabis flowers cultivated in Germany under our newly expanded cultivation license. This launch underscores our commitment to empowering patients and healthcare practitioners with high-quality, locally grown medical cannabis. Stay tuned for more updates as we continue to lead the way in medical cannabis innovation! Details https://lnkd.in/gvbUYq52

  • View organization page for Tilray Medical Europe, graphic

    2,614 followers

    Today, we announced positive results from a study on the use of oral cannabis extract for chemotherapy-induced nausea and vomiting (CINV). This randomized, placebo-controlled trial demonstrated the effectiveness of capsules containing 2.5 mg of THC and 2.5 mg of CBD in reducing CINV symptoms in adults. This advancement underscores Tilray Medical’s commitment to empowering patients and healthcare practitioners with innovative, evidence-based therapeutic options. Learn more https://lnkd.in/gNqDFZdX

  • View organization page for Tilray Medical Europe, graphic

    2,614 followers

    expopharm 2024 is just around the corner - Europe’s biggest pharmacy convention! As market leader for Medicinal Cannabis in Germany, we are proud to be part of it once again and are looking forward to connecting with you in Munich. Date: 9-12 of October Location: Messe München | Tilray Medical booth in Hall B6 - Stand no. E68 Come talk with our team and learn more about our latest product innovation! https://lnkd.in/eq-TYvyt #expopharm

    • No alternative text description for this image
  • View organization page for Tilray Medical Europe, graphic

    2,614 followers

    Tilray Medical is proud to support the AISD Congress in Bergamo, Italy from September 19th – 21st   On Friday, September 20th, Tilray Medical will be hosting an insightful roundtable session on the latest advancements in pain management using cannabis-based extracts. The session is from 13:00-13:30 at in room alabastro A.   Our agenda includes: Introduction to Medical Cannabis  Industrial Cannabis-based Herbal Extracts: Composition and Characteristics  THC and CBD as Major Cannabinoids: Clinical Use in Pain Therapy  New Applications and Future Developments    Don’t miss this opportunity to expand your knowledge and explore new frontiers in pain management.   #MedicalCannabis #PainManagement #CannabisResearch #TilrayMedical  

    • No alternative text description for this image
  • View organization page for Tilray Medical Europe, graphic

    2,614 followers

    EN: Medical Cannabis for Epilepsy #Epilepsy affects millions of people worldwide, and finding effective treatment options is crucial. This is where medical cannabis comes into play. #MedicalCannabis has opened new doors in the treatment of epilepsy. Studies show that cannabidiol (CBD), a compound found in the cannabis plant, can significantly reduce the frequency and severity of seizures. For many patients who do not respond to conventional medications, medical cannabis offers an alternative. At #Tilray, we are deeply committed to researching and providing high-quality medical cannabis. #Health #Therapy #TilrayMedical DE: Medizinisches Cannabis und Epilepsie #Epilepsie betrifft Millionen von Menschen weltweit und die Suche nach wirksamen Behandlungsmöglichkeiten ist von entscheidender Bedeutung. Hier kommt medizinisches Cannabis ins Spiel. #MedizinischesCannabis hat in der Behandlung von Epilepsie neue Türen geöffnet. Studien zeigen, dass Cannabidiol (CBD), ein Wirkstoff der Cannabispflanze, die Häufigkeit und Schwere von Anfällen erheblich reduzieren kann. Für viele Patienten, die auf herkömmliche Medikamente nicht ansprechen, bietet medizinisches Cannabis eine vielversprechende Alternative. Bei #Tilray engagieren wir uns intensiv für die Erforschung und Bereitstellung von hochwertigem medizinischen Cannabis. Unser Ziel ist es, Epilepsiepatienten zu unterstützen und ihnen Zugang zu sicheren und wirksamen Behandlungsmöglichkeiten zu ermöglichen. #Gesundheit #Therapie #Tilraymedical

    • No alternative text description for this image
  • Tilray Medical Europe reposted this

    View organization page for Tilray Brands, Inc., graphic

    77,237 followers

    Today marks a historic change with the implementation of Germany's Medical Cannabis Act. The law will ease access for patients and enable Tilray to contribute to the German market with cannabis of the highest quality from our advanced cultivation facility in Neumünster, Germany. As a leader in cannabis research and production, we are excited to be a part of this new era of well-being in Europe.

Affiliated pages

Similar pages